Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GlaxoSmithKline spins off Affymax; unit raises $51mm

Executive Summary

GlaxoSmithKline has spun off its Affymax Research Institute drug discovery unit to Patricof & Co. and a group of investors including MPM Capital, Apax Partners, and Sprout Group. The venture capitalists put a total of $51mm into Affymax for a 51% combined ownership.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Spin-Off

Related Companies